Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Mouse VEGFR2/KDR/Flk-1 Antibody, R&D Systems™

Rat Monoclonal Antibody
Supplier: R&D Systems MAB4432
This item is not returnable.
View return policy
Description
VEGFR2/KDR/Flk-1 Monoclonal specifically detects VEGFR2/KDR/Flk-1 in Mouse samples. It is validated for Flow Cytometry, Immunocytochemistry, CyTOF-ready.Specifications
VEGFR2/KDR/Flk-1 | |
Monoclonal | |
LYOPH | |
Flow Cytometry 2.5 ug/10^6 cells, Immunocytochemistry 8-25 ug/mL, CyTOF-ready | |
P35918 | |
KDR | |
Mouse myeloma cell line NS0-derived recombinant mouse VEGFR2/KDR/Flk-1, Ala20-Glu762, Accession # P35918 | |
100 μg | |
Primary | |
Detects mouse VEGFR2/KDR/Flk-1. | |
Mouse | |
Purified |
Flow Cytometry, Immunocytochemistry, CyTOF | |
522302 | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), KRD1, Ly73, Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGF R2, VEGFR, VEGFR2, VEGFR-2 | |
Rat | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
3791 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction